AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03662087 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HMA+DLI
Description: HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study NCT01812707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen
Study NCT00701935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, twice a day, 10mcg
Study NCT03457337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Gefitinib
Description: S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
Study NCT03457337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib: 250mg, 1 day, orally
Study NCT03662087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLI
Description: DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study NCT04664569 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: observational study
Study NCT00569231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candida Antigen
Description: Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
Study NCT00683332 — intervention group
Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
Study NCT02962648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Study NCT03970629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty
Study NCT01394731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT02897453 — intervention group
Intervention type: DEVICE
Intervention: The Spinal Tethering System
Description: An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
Study NCT04477083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalable hydroxychloroquine (HCQ)
Description: inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
Study NCT01394731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study NCT04477083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: supportive and symptomatic treatment
Description: supportive and symptomatic treatment
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Oral Ethanol
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study NCT04134533 — intervention group
Intervention type: OTHER
Intervention: Gross Motor Function Measurement
Description: These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
Study NCT02230085 — intervention group
Intervention type: OTHER
Intervention: Administration of the questionnaire and monitoring of CPAP adherence
Study NCT02450760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social incentive
Description: Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
Study NCT04400383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB011 Injection
Description: Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation.
Study NCT03238664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of bladder tumor
Study NCT03238664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound Ablation
Description: Undergo laparoscopic HIFU
Study NCT04230473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study NCT01265329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative selection
Description: Sperm selection to continue the treatment with healthy sperm
Study NCT03926507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT03926507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT03926507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT04833647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardio-Pulmonary-Exercise-Testing (CPET)
Description: Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
Study NCT01810588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® CD34 Reagent System
Description: The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
Study NCT02477007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
Study NCT02477007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (rabbit)
Description: Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
Study NCT01810588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
Study NCT01810588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
Study NCT04065438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPOSORBER® LA-15
Description: LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia).
Study NCT01673139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise
Description: 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
Study NCT01673139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
Study NCT01673139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Given information on recommendations for physical activity.
Study NCT04291963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGG + TUN
Description: In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
Study NCT04291963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTG + TUN
Description: In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
Study NCT00305058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.05 mg/kg Intravenous
Study NCT00305058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.0075 mg/kg intravenous
Study NCT01109992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise plus Regadenoson (Lexercise)
Description: Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
Study NCT01109992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson (Lexiscan)
Description: Regadenoson Rubidium-82 Positron Emission Tomography
Study NCT04644328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday
Description: Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
Study NCT03186846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multimodal monitoring
Description: LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
Study NCT03186846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
Study NCT02124967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A one hour exercise class including both aerobic activity and resistance training
Study NCT02427529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
Study NCT02427529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02427529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Study NCT02427529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Study NCT04254900 — intervention group
Intervention type: OTHER
Intervention: evaluating energy availability
Description: energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
Study NCT00958035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic 0.03% solution
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study NCT02477007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol + ibuprofen
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study NCT00958035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle sterile solution (placebo)
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study NCT01693432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS (docetaxel+S-1)
Description: Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14
Study NCT02477007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
Study NCT02477007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
Study NCT03054961 — intervention group
Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
Study NCT01183845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy
Description: Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
Study NCT02410070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision
Description: The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
Study NCT02410070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision
Description: The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
Study NCT01318785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Armsleeves
Description: Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.
Study NCT03238664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03238664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03238664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo RARC
Study NCT03202511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid Oral Tablet
Description: Included in arm/group descriptions.
Study NCT03202511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: Included in arm/group descriptions.
Study NCT03202511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: Included in arm/group descriptions.
Study NCT00545181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal acidifying gel (RepHresh)
Description: placement of vaginal acidifying gel into vagina to restore normal vaginal pH.
Study NCT00545181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole control
Description: oral metronidazole therapy alone
Study NCT03276533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
Study NCT03238664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Cystectomy
Description: Undergo RARC
Study NCT03238664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo CEUS